Table 1 Characteristics of the 15 patients with MTX-LPD
No | Age range | Underlying disease | Length of MTX (mo) | Final dose (mg/wk) | sIL-2R (U/ml) | LDH (U/L) | PS | Histological type | EBV infection | Stage | IPI | Prognosis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 70s | RA | 48 | 8 | 259 | 212 | 0 | FL | - | I | 1 | non-CR |
2 | 70s | RA | 138 | 6 | 5861 | 190 | 3 | DLBCL | - | IV | 4 | non-CR |
3 | 60s | RA | 234 | 8 | 3744 | 292 | 3 | - | + | III | 4 | non-CR |
4 | 70s | RA | 103 | 6 | 310 | 241 | 1 | MALT lymphoma | N/A | II | 2 | CR |
5 | 60s | PN | 40 | 15 | 670 | 254 | 1 | DLBCL | + | IV | 4 | non-CR |
6 | 50s | PA | 83 | 10 | 3157 | 336 | 2 | - | + | IV | 3 | CR |
7 | 50s | RA | 101 | 10 | 737 | 229 | 0 | polymorphic BLPD | - | III | 1 | non-CR |
8 | 70s | RA | 50 | 8 | 864 | 209 | 1 | polymorphic BLPD | + | IV | 3 | CR |
9 | 70s | RA | 13 | 4 | 503 | 221 | 1 | DLBCL | - | IE | 1 | CR |
10 | 40s | RA | 7 | 8 | 758 | 149 | 0 | - | N/A | II | 0 | CR |
11 | 50s | RA | 48 | 6 | 340 | 176 | 1 | polymorphic BLPD | + | IIE | 0 | CR |
12 | 40s | RA | 48 | 16 | 1370 | 192 | 1 | - | - | III | 1 | CR |
13 | 60s | RA | 116 | 8 | 1136 | 242 | 1 | DLBCL | - | IV | 3 | CR |
14 | 50s | RA | 60 | 16 | 852 | 231 | 1 | MZL | + | IV | 3 | non-CR |
15 | 60s | RA | 172 | 8 | 402 | 252 | 0 | DLBCL | + | IV | 4 | CR |